p53, c-erbB-2 and Ki-67 protein expression and microvessel density (MVD) determined by CD34 antibody were evaluated by immunohistochemistry and their correlation with clinicopathological parameters including estrogen (ER) and progesterone (PR) receptor status and survival were investigated in patients with axillary lymph node-negative infiltrating ductal breast carcinoma.
Methods
The study population consisted of 47 patients with axillary lymph node-negative infiltrating ductal breast carcinoma.
Results
p53 and c-erbB-2 expression was detected in 36.2% and 31.9% of patients, respectively. Median Ki-67 expression was 10%. There were no statistically significant differences in the distribution of p53, Ki-67 and c-erbB-2 protein expression in relation to the age of the patients or to the size, histological grade or ER and PR status of the tumors. p53 protein expression correlated positively with c-erbB-2 and Ki-67 protein expression (P <0.05). The mean MVD was 63.65 ± 29.1 and it correlated positively with histological grade and Ki-67 expression (P <0.05). Survival analysis revealed that age, tumor size, p53 and c-erbB-2 expression and PR status had no significant prognostic impact, whereas histological grade, proliferative activity and angiogenic activity were significant prognostic factors. Although ER-positive patients had a statistically significant overall survival advantage, the difference in disease-free survival was not significant.
Conclusion
In axillary lymph node-negative breast carcinoma the histological grade and the proliferative and angiogenic activity of the tumor could be useful prognostic indicators.
Early Breast Cancer Trialists’ Collaborative Group:Systemic treatment of early breast carcinoma by hormonal, cytotoxic, or immunotherapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Lancet,339: 1–15, 1992.
2.
BoydJ.: Molecular medicine quietly comes of age.Cancer,74: 2215–2217, 1994.
3.
OsborneR.J., MerloG.R., MitsudomiT., VenesioT., LisciaD.S., CappaA.P.M., ChibaI., TakahashiT., NauM.M., CallahanR., MinnaJ.D.: Mutations in the p53 gene in primary human breast cancer.Cancer Res,51: 6194–6198, 1991.
4.
MichalovitzD., HalevyO., OrenM.: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.Cell,62: 671–680, 1990.
5.
McGuireW.L.: Prognostic factors for recurrence and survival in human breast cancer.Breast Cancer Res Treat,10: 5–9, 1987.
6.
SlamonD.J., ClarkG.M., WongS.G., LevinW.J., UllrichA., McGuireW.L.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science,235: 177–182, 1987.
7.
RossJ.S., FletcherJ.A.: HER-2/neu (c-erbB-2) gene and protein in breast cancer.J Clin Pathol,112(suppl. 1): 53–67, 1999.
8.
WeidnerN., SempleJ.P., WelchW.R., FolkmanJ.: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma.N Engl J Med,324: 1–8, 1991.
9.
BosariS., LeeA.K., DeLellisR.A., WileyB.D., HeatleyG.J., SilvermanM.L.: Microvessel quantitation and prognosis in invasive breast carcinoma.Hum Pathol,23: 755–761, 1992.
10.
FoxS.B., LeekR.D., SmithK., HollyerJ., GreenallM., HarrisA.L.: Tumor angiogenesis in node-negative patients: relationship with epidermal growth factor receptor, estrogen receptor, and survival.Breast Cancer Res Treat,29: 109–116, 1994.
11.
CostelloP., McCannA., CarneyD.N., DervanP.A.: Prognostic significance of microvessel density in lymph node negative breast carcinoma.Hum Pathol,26: 1181–1184, 1995.
12.
HallN.R., FishD.E., HuntN., GoldinR.D., GuillouP.J., MonsonJ.R.: Is the relationship between angiogenesis and metastasis in breast cancer real?Surg Oncol,1: 223–229, 1992.
13.
ReedW., HannisdalE., BoehlerP.J., GundersenS., HostH., NeslandJ.M.: The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.Cancer,88: 804–813, 2000.
14.
RudasM., NeumayerR., GnantM.F., MittelböckM., JakeszR., ReinerA.: p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.Eur J Cancer,33: 39–44, 1997.
15.
GancbergD., LespagnardL., RouasG., PaesmansM., PiccartM., Di LeoA., NogaretJ.M., HertensD., VerhestA., LarsimontD.: Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.Am J Clin Pathol,113: 675–682, 2000.
16.
KatoT., KameokaS., KimuraT., NishikawaT., KasajimaT.: Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer.Breast Cancer Res Treat,70: 65–74, 2001.
17.
ElstonC.W., EllisI.O.: Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up.Histopathology,19: 403–410, 1991.
18.
ClaytonF.: Pathologic correlates of survival in 378 lymph node negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor.Cancer,68: 1309–1317, 1991.
19.
LampeB., HantschmannP., DimpflT.: Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary lymph node negative breast cancer.Arch Gynecol Obstet,261: 139–146, 1998.
20.
SearsH.F., JanusC., LevyW., HopsonR., CreechR., GrotzingerP.: Breast cancer without axillary metastasis.Are there high-risk biologic subpopulations? Cancer,50: 1820–1827, 1982.
21.
Van de VeldeC.J.H., GallagerH.S., GiaccoG.G.: Prognosis in node-negative breast cancer.Breast Cancer Res Treat,8: 189–196, 1986.
22.
ElledgeR.M., AllredD.C.: The p53 tumor suppressor gene in breast cancer.Breast Cancer Res Treat,32: 39–47, 1994.
23.
FresnoM., MolinaR., Pérez del RioM.J., AlvarezS., Diaz-IglesiasJ.M., GarciaI., HerreroA.: P 53 expression is of independent predictive value in lymph node negative breast carcinoma.Eur J Cancer,33: 1268–1274, 1997.
24.
JiH., LipponenP., AaltomaaS., SyrjänenS., SyrjänenK.: cerbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.Anticancer Res,13: 1147–1152, 1993.
25.
MolinaR., SeguiM.A., ClimentM.A., BellmuntJ., AlbanellJ., FernandezM., FilellaX., JoJ., GimenezN., IglesiasE., MirallesM., AlonsoC., PeiroG., Perez-PianolE., BallestaA.M.: P53 oncoprotein as a prognostic indicator in patients with breast cancer.Anticancer Res,18: 507–511, 1998.
26.
BianchiS., CalzolariA., VezzosiV., ZampiG., CardonaG., CataliottiL., BonardiR., CiattoS.: Lack of prognostic value of p53 protein expression in node-negative breast cancer.Tumori,83: 669–672, 1997.
27.
O'MalleyF.P., SaadZ., KerkvlietN., GoigG., StittL., AinsworthP., HundalH., ChambersA.F., TurnbullD.I., BramwellV.: The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer.Hum Pathol, 27: 955–963, 1996.
28.
AlbanellJ., BellmuntJ., MolinaR., GarciaM., CaragolI., BermejoB., RibasA., CarullaJ., GallegoO.S., EspanolT., Sole CalvoL.A.: Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.Anticancer Res,16: 1027–1032, 1996.
29.
RosenP.P., LesserM.L., ArroyoC.D., CranorM., BorgenP., NortonL.: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.Cancer,75: 1320–1326, 1995.
30.
NakopoulouL.L., AlexiadouA., TheodoropoulosG.E., LazarisA.C.H., TzonouA., KeramopoulosA.: Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.J Pathol,179: 31–38, 1996.
31.
IsolaJ.I., HelinH.J., HelleM.J., KallioniemiO.P.: Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count.Cancer,65: 1180–1184, 1990.
32.
LipponenP., JiH., AaltomaaS., SurjanenK.: Tumor vascularity and basement membrane structure in breast cancer as related to tumour histology and prognosis.J Cancer Res Clin Oncol,120: 645–650, 1994.
33.
MonschkeF., MüllerW.U., WinklerU., SrefferC.: Cell proliferation and vascularization in human breast carcinomas.Int J Cancer,49: 812–815, 1991.
34.
YokotoT., ImamuraM., TeshimaS., SuzukiH., TezukaF., KikuchiS., KuniiY., YamauchiH.: C-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.Anticancer Res,19: 4007–4012, 1999.
35.
BarbareschiM., LeonardiE., MauriF., SerioG., PalmaP.D.: p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers and clinical stage in human breast cancer.Am J Clin Pathol,98: 408–418, 1992.
36.
SaimuraM., FukutomiT., TsudaH., SatoH., MiyamotoK., Akashi-TanakaS., NanasawaT.: Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor.J Surg Oncol,71: 101–105, 1999.
